78,520 Shares in Boston Scientific Corporation $BSX Purchased by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the second quarter, HoldingsChannel.com reports. The firm purchased 78,520 shares of the medical equipment provider’s stock, valued at approximately $3,351,000.

Several other hedge funds and other institutional investors have also modified their holdings of BSX. Kelleher Financial Advisors purchased a new stake in shares of Boston Scientific during the second quarter valued at approximately $25,000. FWL Investment Management LLC acquired a new stake in Boston Scientific during the 2nd quarter valued at $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific during the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific during the 4th quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific in the 1st quarter worth $28,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Up 0.3%

Boston Scientific stock opened at $46.82 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The company has a 50-day simple moving average of $46.56 and a 200-day simple moving average of $56.65. The firm has a market capitalization of $67.85 billion, a P/E ratio of 18.96, a P/E/G ratio of 1.02 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the business posted $0.75 EPS. Boston Scientific’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

Several research firms have recently weighed in on BSX. Needham & Company LLC cut their target price on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Mizuho decreased their price target on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. TD Cowen reissued a “buy” rating and issued a $56.00 price objective on shares of Boston Scientific in a report on Tuesday. Evercore set a $65.00 price objective on Boston Scientific in a research note on Monday, July 6th. Finally, Canaccord Genuity Group decreased their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $71.62.

Insider Buying and Selling

In other Boston Scientific news, Director David C. Habiger purchased 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael F. Mahoney purchased 186,240 shares of the stock in a transaction dated Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 194,522 shares of company stock valued at $9,385,210 in the last three months. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.